Epidermicin NI01 demonstrates potent in vivo activity in a murine model of methicillin-resistant Staphylococcus aureus skin infection
Vicky Bennett, Gordon Barker, Andrew Sharp, Victoria L Birkett, Jennifer Williams, Pani Tourlomousis, Mathew Upton · 2026
Read Epidermicin NI01 demonstrates potent in vivo activity in a murine model of methicillin-resistant Staphylococcus aureus skin infection by Vicky Bennett, Gordon Barker, Andrew Sharp, Victoria L Birkett, Jennifer Williams, Pani Tourlomousis, Mathew Upton (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13278623.txt.
Description
Vicky Bennett leads a 2026 mouse study of a new bacteria-killing compound for skin infections caused by MRSA, a drug-resistant Staphylococcus strain. The compound, epidermicin NI01, is a bacteriocin, a natural antimicrobial made by bacteria, with a novel mode of action. Infected skin on immunosuppressed mice was treated daily with the compound or with standard antibiotic creams.
No adverse effects appeared from infection or treatment. A single-dose group showed no benefit, but repeated three percent dosing cut bacterial counts about as much as the standard creams. The dose needed to kill the test strain stayed unchanged after treatment. Further development is warranted, the authors say, and clinical use could spare standard antibiotics for severe infections.
Catalog record
| CREATOR | Vicky Bennett, Gordon Barker, Andrew Sharp, Victoria L Birkett, Jennifer Williams, Pani Tourlomousis, Mathew Upton |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 25266 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |